| Identification | Back Directory | [Name]
L-α-Glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginylglycine | [CAS]
392661-17-5 | [Synonyms]
L-α-Glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginylglycine | [Molecular Formula]
C164H255N47O37S | [MOL File]
392661-17-5.mol | [Molecular Weight]
3509.14 |
| Hazard Information | Back Directory | [Uses]
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research[1][2]. | [in vivo]
PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo[1].
PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor [1]. | Animal Model: | Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1] | | Dosage: | 2 mg/mouse | | Administration: | Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr | | Result: | No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor. |
| Animal Model: | Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1] | | Dosage: | 1 mg/mouse, 10 mg/mouse and 20 mg/mouse | | Administration: | When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days | | Result: | Resulted in a significant level of tumor growth inhibition in a dose-related manner. |
| [References]
[1] Michl J, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006 Oct 1;119(7):1577-85. DOI:10.1002/ijc.22029
[2] Kelley A. Sookraj. QS304. Novel p53-Derived Peptide Induces Rapid Human Pancreatic Cancer Cell Death. 2008, 144(2), 1. |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 |
| Website: |
|
| Company Name: |
Fuan Bio
|
| Tel: |
15002819872 |
| Website: |
fuanbio.com |
|